Abstract

Medulloblastoma is the second most common and most malignant brain tumor in children. But in adults medulloblastomas occur rarely. The patients with medulloblastoma are stratified two groups before treatment: avarage risk and high risk. Surgical resection followed by craniospinal irradiation (CSI) has been the mainstay of medulloblastoma therapy. In recent years, chemotherapy has been introduced to reduce the total dose of radiation and increase the survival rate. The new radiotherapy techniques and chemotherapy agents increase compliance to treatment.